2019―2023年湖北省流行性腮腺炎流行病学特征

葛胜辉; 石玉琴; 王雷; 张玲; 童叶青

doi:10.16462/j.cnki.zhjbkz.2025.06.017

2019―2023年湖北省流行性腮腺炎流行病学特征

doi: 10.16462/j.cnki.zhjbkz.2025.06.017

葛胜辉¹,
石玉琴¹,
王雷²,
张玲^1, ,,
童叶青^2, ,

1.
武汉科技大学医学部公共卫生学院环境卫生与职业医学系，武汉 430065
2.
湖北省疾病预防控制中心传染病预防控制所，武汉 430079

基金项目:

国家自然科学基金 92169117

湖北省高等学校优秀中青年科技创新团队计划 T2020003

详细信息

通讯作者:
童叶青，E-mail: 63382251@qq.com

张玲，E-mail: zhangling@wust.edu.cn

中图分类号: R183;R181
计量
- 文章访问数: 6
- HTML全文浏览量: 1
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2024-10-08
- 修回日期: 2025-02-24
- 网络出版日期: 2025-07-07
- 刊出日期: 2025-06-10

Epidemiological characteristics of mumps in Hubei Province from 2019 to 2023

GE Shenghui¹,
SHI Yuqin¹,
WANG Lei²,
ZHANG Ling^{1
, ,},
TONG Yeqing^{2
, ,}

1.
Department of Environmental Health and Occupational Medicine, School of Public Health, Faculty of Medicine of Wuhan University of Science and Technology, Wuhan 430065, China
2.
Infectious Disease Prevention and Control Institute, Hubei Provincial Center for Disease Control and Prevention, Wuhan 430079, China

Funds:

National Natural Science Foundation of China 92169117

Hubei Provincial Outstanding Young and Middle-aged Scientific and Technological Innovation Team Program T2020003

More Information

Corresponding author: ZHANG Ling, E-mail: zhangling@wust.edu.cn; TONG Yeqing, E-mail: 63382251@qq.com

摘要

摘要: 目的分析2019―2023年湖北省流行性腮腺炎(简称流腮)的流行病学特征，为流腮防控提供科学依据。方法基于2019―2023年中国疾病预防控制信息系统中湖北省流腮患者的流行病学史、临床诊断个案数据，年龄范围为全人群，整理报告卡信息包括性别、年龄、时间分布、人群分布和地区分布等。采用χ²检验或Fisher确切概率法分析其流行病学特征。结果 2019―2023年湖北省共报告流腮36 154例，年均报告发病率为12.33/10万。2019年流腮年均报告发病率(27.35/10万)和发病构成比(44.84%)最高，2020―2023年逐步降低。时间分布上，流腮发病主要集中在春季、夏季和秋季，不同月份发病比率差异均有统计学意义(均P＜0.001)。性别分布上，男性流腮发病比率(59.43%)高于女性(40.57%)，差异均有统计学意义(均P＜0.001)。年龄分布上，2019―2023年流腮高发年龄为0~＜20岁，≥60岁老年人不易发病，不同年龄发病率差异均有统计学意义(均P＜0.001)。人群分布上，学生(52.86%)和幼托儿童(25.91%)的流腮发病比率较其他人群高，差异均有统计学意义(均P＜0.001)。湖北省不同城市流腮发病比率差异有统计学意义(P＜0.001)。结论 2019―2023年湖北省人群流腮发病率总体上呈下降趋势，春季、夏季和秋季高发，高发年龄为0~＜20岁，应重点关注儿童，加强对学校和幼托机构的防控力度。
- 流行性腮腺炎 /
- 含腮腺炎成分疫苗 /
- 流行病学特征
Abstract: Objective To analyze the epidemiological characteristics of mumps in Hubei Province from 2019 to 2023, to provide a scientific basis for subsequent prevention and control of mumps. Methods Based on the epidemiological history and clinical diagnosis case data of mumps patients in Hubei Province from the China Disease Prevention and Control Information System between 2019 and 2023, and covering the entire population regarding age range, the report card information including gender, age, temporal distribution, population distribution, and regional distribution was organized. The χ² test and Fisher′s exact test were used to analyze its epidemiological characteristics. Results From 2019 to 2023, Hubei Province reported a total of 36 154 mumps cases, and the average annual incidence rate was 12.33/100 000. The highest incidence rate (27.35/100 000) and proportion of cases (44.84%) were reported in 2019, with a gradual decrease in incidence rate and proportion from 2020 to 2023. The disease primarily occurred in spring, summer, and autumn, with statistically significant differences in the incidence proportion across months (all P < 0.001). The incidence proportion in males (59.43%) was higher than in females (40.57%), with significant differences across gender (P < 0.001). The high-risk age group for mumps from 2019 to 2023 was 0- < 20 years, but individuals over 60 less affected, and there were significant statistical differences across age groups (all P < 0.001). Students (52.86%) and young children (25.91%) had a higher incidence proportion compared to other populations, with significant differences across different populations (all P < 0.001). There difference in the incidence proportion of mumps among different cities in Hubei province also showed significant differences (P < 0.001). Conclusions From 2019 to 2023, the overall incidence rate of mumps in Hubei Province showed a downward trend. The disease is prevalent in spring, summer, and autumn, with a high incidence in individuals aged 0- < 20 years. Preventive and control efforts should focus on children, particularly in schools and childcare institutions.
- Mumps /
- Mumps containing vaccine /
- Epidemiological characteristics

HTML全文

图 1 2019―2023年湖北省流行性腮腺炎报告病例月分布

Figure 1. Monthly distribution of reported epidemic mumps cases in Hubei Province from 2019 to 2023

下载: 全尺寸图片幻灯片

图 2 2019―2023年湖北省不同年龄组流行性腮腺炎报告发病率

Figure 2. Incidence rates of reported epidemic mumps in different age groups in Hubei Province from 2019 to 2023

下载: 全尺寸图片幻灯片

图 3 2019―2023年湖北省不同人群流行性腮腺炎报告发病例数构成比

Figure 3. Proportional composition of reported cases of epidemic mumps among different occupations in Hubei Province from 2019 to 2023

下载: 全尺寸图片幻灯片

图 4 2019―2023年湖北省不同地市流行性腮腺炎报告发病情况柱状图

Figure 4. Bar chart of reported cases of epidemic mumps in different cities of Hubei Province from 2019 to 2023

下载: 全尺寸图片幻灯片

参考文献(29)

[1]	Bedford H. Mumps: current outbreaks and vaccination recommendations[J]. Nursing Times, 2005, 101(39): 53-54, 56.
[2]	Hviid A, Rubin S, Mühlemann K. Mumps[J]. Lancet, 2008, 371(9616): 932-944. DOI: 10.1016/S0140-6736(08)60419-5.
[3]	Su SB, Chang HL, Chen AK. Current status of mumps virus infection: epidemiology, pathogenesis, and vaccine[J]. Int J Environ Res Public Health, 2020, 17(5): 1686. DOI: 10.3390/ijerph17051686.
[4]	Connell AR, Connell J, Ronan Leahy T, et al. Mumps outbreaks in vaccinated populations-is it time to re-assess the clinical efficacy of vaccines?[J]. Front Immunol, 2020, 11: 2089. DOI: 10.3389/fimmu.2020.02089.
[5]	Ennis FA, Jackson D. Isolation of virus during the incubation period of mumps infection[J]. J Pediatr, 1968, 72(4): 536-537. DOI: 10.1016/s0022-3476(68)80347-6.
[6]	Beleni AI, Borgmann S. Mumps in the vaccination age: global epidemiology and the situation in Germany[J]. Int J Environ Res Public Health, 2018, 15(8): 1618. DOI: 10.3390/ijerph15081618.
[7]	Marshall HS, Plotkin S. The changing epidemiology of mumps in a high vaccination era[J]. Lancet Infect Dis, 2019, 19(2): 118-119. DOI: 10.1016/S1473-3099(18)30541-3.
[8]	Wen L, Yang DL, Li YN, et al. Spatial effect of ecological environmental factors on mumps in China during 2014-2018[J]. Int J Environ Res Public Health, 2022, 19(23): 15429. DOI: 10.3390/ijerph192315429.
[9]	Fan Y, Yang M, Jiang H, et al. Estimating the effectiveness of early control measures through school absenteeism surveillance in observed outbreaks at rural schools in Hubei, China[J]. PLoS One, 2014, 9(9): e106856. DOI: 10.1371/journal.pone.0106856.
[10]	Ding Y, Sauerborn R, Xu B, et al. A cost-effectiveness analysis of three components of a syndromic surveillance system for the early warning of epidemics in rural China[J]. BMC Public Health, 2015, 15: 1127. DOI: 10.1186/s12889-015-2475-x.
[11]	Cui AL, Zhu Z, Hu Y, et al. Mumps epidemiology and mumps virus genotypes circulating in mainland China during 2013-2015[J]. PLoS One, 2017, 12(1): e0169561. DOI: 10.1371/journal.pone.0169561.
[12]	Lin SQ, Ruan SM, Geng XY, et al. Non-linear relationships and interactions of meteorological factors on mumps in Jinan, China[J]. Int J Biometeorol, 2021, 65(4): 555-563. DOI: 10.1007/s00484-020-02048-y.
[13]	Zhou ZF, Mei SJ, Chen J, et al. Nonlinear effect of wind velocity on mumps in Shenzhen, China, 2013-2016[J]. Public Health, 2020, 179: 178-185. DOI: 10.1016/j.puhe.2019.10.023.
[14]	Hara M, Koshida R, Nakano T. Parents' views on mumps, mumps vaccine, and the factors associated with vaccination in Japan[J]. Vaccine, 2021, 39(52): 7677-7683. DOI: 10.1016/j.vaccine.2021.11.015.
[15]	Kauffmann F, Heffernan C, Meurice F, et al. Measles, mumps, rubella prevention: how can we do better?[J]. Expert Rev Vaccines, 2021, 20(7): 811-826. DOI: 10.1080/14760584.2021.1927722.
[16]	Chen BZ, Wang ML, Huang X, et al. Changes in incidence of notifiable infectious diseases in China under the prevention and control measures of COVID-19[J]. Front Public Health, 2021, 9: 728768. DOI: 10.3389/fpubh.2021.728768.
[17]	Xiao JP, Dai JY, Hu JX, et al. Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: a large population-based observational study[J]. Lancet Reg Health West Pac, 2021, 17: 100282. DOI: 10.1016/j.lanwpc.2021.100282.
[18]	疾病预防控制局. 关于国家免疫规划脊髓灰质炎疫苗和含麻疹成分疫苗免疫程序调整相关工作的通知[EB/OL]. (2020-01-07)[2025-02-03]. http://www.nhc.gov.cn/jkj/s3589/202001/ba151e4ad7824ad6950d8d24879a2235.shtml.
[19]	Sun J, Yang WW, Zeng LJ, et al. Surveillance data on notifiable infectious diseases among students aged 6-22 years in China, 2011-2016[J]. Chin J Epidemiol, 2018, 39(12): 1589-1595. DOI: 10.3760/cma.j.issn.0254-6450.2018.12.010.
[20]	Peng Y, Yang TL, Zhu YZ, et al. Estimating the transmissibility of mumps: a modelling study in Wuhan City, China[J]. Front Med, 2021, 8: 683720. DOI: 10.3389/fmed.2021.683720.
[21]	Zhang H, Su K, Zhong XN. Association between meteorological factors and mumps and models for prediction in Chongqing, China[J]. Int J Environ Res Public Health, 2022, 19(11): 6625. DOI: 10.3390/ijerph19116625.
[22]	Onozuka D, Hashizume M. Effect of weather variability on the incidence of mumps in children: a time-series analysis[J]. Epidemiol Infect, 2011, 139(11): 1692-1700. DOI: 10.1017/S0950268810002967.
[23]	Dayan GH, Patricia Quinlisk M, Parker AA, et al. Recent resurgence of mumps in the United States[J]. N Engl J Med, 2008, 358(15): 1580-1589. DOI: 10.1056/NEJMOa0706589.
[24]	Shepersky L, Marin M, Zhang J, et al. Mumps in vaccinated children and adolescents: 2007-2019[J]. Pediatrics, 2021, 148(6): e2021051873. DOI: 10.1542/peds.2021-051873.
[25]	Perez Duque M, San-Bento A, Léon L, et al. Mumps outbreak among fully vaccinated school-age children and young adults, Portugal 2019/2020[J]. Epidemiol Infect, 2021, 149: e205. DOI: 10.1017/S0950268821002028.
[26]	Sun X, Tang FY, Hu Y, et al. High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China[J]. Hum Vaccin Immunother, 2020, 16(7): 1738-1742. DOI: 10.1080/21645515.2019.1708162.
[27]	Elbadawi LI, Talley P, Rolfes MA, et al. Non-mumps viral parotitis during the 2014-2015 influenza season in the United States[J]. Clin Infect Dis, 2018, 67(4): 493-501. DOI: 10.1093/cid/ciy137.
[28]	Won H, Kim AR, Yoo JS, et al. Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea[J]. Vaccine, 2021, 39(13): 1870-1876. DOI: 10.1016/j.vaccine.2021.01.039.
[29]	Lewnard JA, Grad YH. Vaccine waning and mumps re-emergence in the United States[J]. Sci Transl Med, 2018, 10(433): eaao5945. DOI: 10.1126/scitranslmed.aao5945.